Impel NeuroPharma is developing transformative therapies for people suffering from central nervous system disorders with high unmet medical needs. We are developing therapies that have the potential to deliver injection-like clinical outcomes via our proprietary formulations and upper nasal delivery technology – Precision Olfactory Delivery (POD). Our POD technology is designed to target the vascular-rich upper nasal cavity with multiple clinical trials demonstrating rapid absorption and consistent drug biodistribution with ease of use for a patient, provider or caregiver. We have late stage clinical development programs to address patient needs in acute migraine, treatment of OFF episodes in Parkinson’s disease and acute agitation in schizophrenia and bipolar I disorder. We strive to create life-changing, innovative therapies for CNS diseases.
Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DH...
Impel NeuroPharma today announced the appointment of John Leaman, M.D., as the Company’s Chief Financial Officer. ...
Phase 1 Data Support Selection of Company’s Proprietary Formulation of Investigational Nasal Olanzapine, INP105, Currently Be...